Merck & Co., Inc. (NYSE:MRK) Sets New 52-Week High on Analyst Upgrade

Merck & Co., Inc. (NYSE:MRK)’s share price hit a new 52-week high during mid-day trading on Wednesday after Bank of America raised their price target on the stock from $130.00 to $141.00. Bank of America currently has a buy rating on the stock. Merck & Co., Inc. traded as high as $130.29 and last traded at $128.41, with a volume of 11819460 shares trading hands. The stock had previously closed at $129.38.

MRK has been the topic of several other reports. UBS Group boosted their price target on shares of Merck & Co., Inc. from $130.00 to $145.00 and gave the stock a “buy” rating in a research report on Monday, April 13th. Zacks Research upgraded Merck & Co., Inc. from a “strong sell” rating to a “hold” rating in a report on Tuesday, March 17th. JPMorgan Chase & Co. increased their price target on Merck & Co., Inc. from $125.00 to $135.00 and gave the company an “overweight” rating in a research report on Monday, April 6th. Citigroup started coverage on Merck & Co., Inc. in a research report on Wednesday, May 6th. They set a “neutral” rating and a $125.00 price target on the stock. Finally, Scotiabank upped their price objective on Merck & Co., Inc. from $136.00 to $155.00 and gave the stock a “sector outperform” rating in a research note on Tuesday. One research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and seven have given a Hold rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $131.83.

Merck & Co., Inc. News Roundup

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Bank of America raised its price target on Merck to $141 from $130 and reiterated a buy rating, while Scotiabank lifted its target to $155 from $136 with a sector outperform view, signaling stronger Wall Street confidence in the stock’s upside. Bank of America and Scotiabank raise Merck price targets
• Positive Sentiment: Analysts also highlighted Merck’s lung cancer drug pipeline, saying an upcoming phase 3 readout for OptiTrop-Lung06 could improve the commercial outlook for SAC-TMT and boost future sales potential. Merck’s Lung Cancer Drug Seen Boosting Sales Potential, BofA Says
• Positive Sentiment: Merck announced an agreement with the ADAP Crisis Task Force to improve access to HIV treatment through state programs, which may modestly support sentiment around its infectious-disease franchise. Merck Announces New Agreement with ADAP Crisis Task Force
• Neutral Sentiment: Broader healthcare stocks were softer late Tuesday, which may have added some pressure even as Merck continued to attract company-specific buying interest. Sector Update: Healthcare Stocks Softer Late Afternoon
• Negative Sentiment: Merck is also facing a bipartisan U.S. House investigation into whether clinical trials conducted in China, including at military-linked hospitals and in Xinjiang, raised national security or data-protection concerns, which could weigh on sentiment if the probe escalates. Merck (MRK) Faces U.S. Security Probe Over China Clinical Trials

Institutional Trading of Merck & Co., Inc.

Institutional investors have recently modified their holdings of the business. Chesapeake Wealth Management increased its position in shares of Merck & Co., Inc. by 0.6% during the fourth quarter. Chesapeake Wealth Management now owns 14,740 shares of the company’s stock worth $1,552,000 after buying an additional 87 shares during the period. South Plains Financial Inc. raised its stake in Merck & Co., Inc. by 0.6% during the 4th quarter. South Plains Financial Inc. now owns 15,535 shares of the company’s stock worth $1,635,000 after buying an additional 89 shares during the period. Syverson Strege & Co lifted its holdings in shares of Merck & Co., Inc. by 2.2% in the 4th quarter. Syverson Strege & Co now owns 4,142 shares of the company’s stock worth $436,000 after purchasing an additional 90 shares in the last quarter. Nations Financial Group Inc. IA ADV grew its holdings in shares of Merck & Co., Inc. by 0.4% during the first quarter. Nations Financial Group Inc. IA ADV now owns 23,433 shares of the company’s stock valued at $2,819,000 after buying an additional 91 shares during the last quarter. Finally, Westside Investment Management Inc. grew its holdings in shares of Merck & Co., Inc. by 3.1% during the fourth quarter. Westside Investment Management Inc. now owns 3,142 shares of the company’s stock valued at $331,000 after buying an additional 93 shares during the last quarter. Institutional investors own 76.07% of the company’s stock.

Merck & Co., Inc. Trading Down 0.7%

The company has a quick ratio of 1.06, a current ratio of 1.30 and a debt-to-equity ratio of 1.02. The company has a market capitalization of $317.15 billion, a P/E ratio of 36.17, a P/E/G ratio of 2.90 and a beta of 0.21. The firm’s 50-day moving average price is $116.54 and its 200 day moving average price is $114.88.

Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings results on Thursday, April 30th. The company reported ($1.28) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.47) by $0.19. The business had revenue of $16.29 billion during the quarter, compared to the consensus estimate of $15.85 billion. Merck & Co., Inc. had a return on equity of 27.55% and a net margin of 13.59%.The company’s quarterly revenue was up 4.9% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.22 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. As a group, equities research analysts predict that Merck & Co., Inc. will post 5.18 earnings per share for the current year.

Merck & Co., Inc. Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, July 8th. Investors of record on Monday, June 15th will be given a $0.85 dividend. This represents a $3.40 dividend on an annualized basis and a yield of 2.6%. The ex-dividend date of this dividend is Monday, June 15th. Merck & Co., Inc.’s dividend payout ratio is presently 95.77%.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.